- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00969917
Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
April 13, 2015 updated by: Infinity Pharmaceuticals, Inc.
A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
The primary objective of the study is to determine the safety profile and overall response rate of IPI 504 in patients with advanced dedifferentiated liposarcoma.
Study Overview
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber Cancer Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- At least 18 years of age at the time of signing informed consent.
- Histologic diagnosis of dedifferentiated liposarcoma.
- Available archival pathology specimen or tissue sample from a new biopsy for confirmation of diagnosis by central pathology reading.
- At least one prior chemotherapy regimen for dedifferentiated liposarcoma.
- No more than 2 prior chemotherapy regimens for dedifferentiated liposarcoma. Note: Any number of non-chemotherapy regimens is permitted.
- Measurable disease on computed tomography (CT) or magnetic resonance imaging (MRI) as defined by RECIST (version 1.1) with at least one measurable lesion.
- Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1.
- Life expectancy ≥6 months.
Exclusion Criteria:
- Prior treatment with any heat shock protein 90 (Hsp90) inhibitor.
- Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease
- Patients with prior hepatic resections or hepatic-directed therapy
- Use of a medication or food that is a clinically relevant CYP3A inhibitor or inducer within 2 weeks prior to dosing.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IPI-504
IPI 504 administered twice weekly for 2 weeks followed by 1 week off treatment
|
IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the safety profile and overall response rate (ORR) of IPI 504 in patients with advanced dedifferentiated liposarcoma.
Time Frame: Every 6 weeks
|
Every 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the clinical benefit rate and duration of overall response
Time Frame: Every 6 weeks
|
Every 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (Anticipated)
December 1, 2010
Study Completion
December 1, 2010
Study Registration Dates
First Submitted
September 1, 2009
First Submitted That Met QC Criteria
September 1, 2009
First Posted (Estimate)
September 2, 2009
Study Record Updates
Last Update Posted (Estimate)
April 14, 2015
Last Update Submitted That Met QC Criteria
April 13, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IPI-504-09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dedifferentiated Liposarcoma
-
Memorial Sloan Kettering Cancer CenterRecruitingSarcoma | Soft Tissue Sarcoma | Sarcoma,Soft Tissue | Dedifferentiated Liposarcoma | Recurrent Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Unresectable Dedifferentiated LiposarcomaUnited States
-
Sarcoma Alliance for Research through CollaborationEli Lilly and CompanyRecruitingAdvanced Dedifferentiated LiposarcomaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Advanced Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Locally Advanced Dedifferentiated Liposarcoma | Unresectable Dedifferentiated...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Osteosarcoma | Refractory Osteosarcoma | Metastatic Osteosarcoma | Metastatic Angiosarcoma | Recurrent Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Recurrent Angiosarcoma | Refractory Dedifferentiated LiposarcomaUnited States
-
Institut BergoniéMinistry of Health, France; PharmaMarTerminatedAdult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated LiposarcomaFrance
-
Mario Negri Institute for Pharmacological ResearchFondazione IRCCS Istituto Nazionale dei Tumori, Milano; Humanitas Hospital,...RecruitingLiposarcoma, Myxoid | Liposarcoma, Dedifferentiated | Liposarcoma, Round CellItaly
-
Boehringer IngelheimRecruitingLiposarcoma, DedifferentiatedUnited States, Australia, Canada, United Kingdom, Japan
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingDedifferentiated LiposarcomaChina
-
Boehringer IngelheimActive, not recruitingLiposarcoma, DedifferentiatedUnited States, Spain, Canada, Taiwan, Belgium, Australia, China, Italy, Germany, Japan, Hong Kong, Finland, United Kingdom, Denmark, France, Sweden, Netherlands, Portugal, Czechia, Greece, Norway
-
European Organisation for Research and Treatment...SanofiCompletedDedifferentiated LiposarcomaUnited Kingdom, Belgium, France, Italy
Clinical Trials on IPI-504
-
Massachusetts General HospitalDana-Farber Cancer Institute; Infinity Pharmaceuticals, Inc.TerminatedLung Cancer | Stage IV Lung Cancer | Stage IIIb Lung CancerUnited States
-
Infinity Pharmaceuticals, Inc.CompletedGastrointestinal Stromal Tumors | Soft Tissue SarcomasUnited States, Canada
-
Infinity Pharmaceuticals, Inc.TerminatedMetastatic MelanomaUnited States
-
Infinity Pharmaceuticals, Inc.Completed
-
Infinity Pharmaceuticals, Inc.CompletedMultiple MyelomaUnited States
-
MedImmune LLCWithdrawnBreast CancerUnited States
-
Infinity Pharmaceuticals, Inc.CompletedProstatic Neoplasms | Prostate Cancer | Cancer of the ProstateUnited States
-
Infinity Pharmaceuticals, Inc.CompletedNon Small Cell Lung CancerUnited States, Hungary, Taiwan, Korea, Republic of, Russian Federation, Romania
-
Bausch Health Americas, Inc.CompletedOnychomycosisUnited States, Dominican Republic
-
Infinity Pharmaceuticals, Inc.AstraZeneca; MedImmune LLCTerminated